Insights

A large international investment in hereditary retinal diseases

The path of AAVantgarde Bio, the Tigem spin-off dedicated to the development of gene therapies for hereditary diseases of the retina, continues at full speed! The company, founded in 2021 thanks to the Sofinnova-Telethon fund, has in fact announced that it has obtained a 61 million euro from three major international investment companies: Atlas Venture, Forbion and Longwood. AAVantgarde Bio will work to bring an innovative gene therapy approach born in the Telethon laboratories to the clinic.

EUROPEAN RESEARCH COUNCIL (ERC): ASSIGNED TO ANDREA BALLABIO AND ALBERTO AURICCHIO TWO ADVANCED GRANTS FOR A TOTAL OF 5 MILLION EUROS

Andrea Ballabio and Alberto Auricchio received the prestigious ERC Advanced Grants, also as evidence of excellence of the Telethon Institute of Genetics and Medicine, capable of attracting the best Italian and international scientists.

ARVO 2023 Annual Meeting Travel Grants

4 Postdoctoral Fellowships in Genomics and Experimental Medicine (GEM)

Cellular metabolism: towards drugs against pathologies that favor the onset of tumours

25/01/2023 UNISA Tigem Meeting Day